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1. Introduction
Dr. Barbara McClintock, the 1983 Nobel Prize winner in physiology or medicine, 
described that “the most remarkable kinds of mutations are not (usually) produced by 
such extrinsic factors as radiation and chemicals, but by factors that are intrinsic to 
the cells themselves”.
Evidences obtained from studies proved that genomic mutations are the direct 
root causes of increased susceptibility to almost all disorders/diseases in the man-
ner of either somatic or germline mutations. Diseases associated with somatic 
mutations have been well studied; in contrast, studies on diseases associated with 
germline mutations have been just started, particularly in malignancies.
The estimation by 2015 showed that there were about 17.5 million cancer cases 
and 8.7 million deaths worldwide per annum [1]. Cancer is a genetic disease caused 
by mutations from environmental and genetic factors and their interactions. 
Genetic factors include somatic (acquired) and germline: the difference between 
germline and somatic mutations is that the germline mutation occurring in repro-
ductive cells (sperm, egg) inherits to the offspring, whereas somatic mutation 
occurring in body cells is not inherent to the offspring.
In the recent years, more and more attention has been paid to the studies on 
cancers associated with germline mutations, and more and more discoveries have 
been achieved by increasing the recognition of such disease. TP53 was the typi-
cal and most commonly germline-mutated gene associated with Li-Fraumeni 
syndrome (colorectal cancer). Studies from Zhang group showed that the rate of 
germline mutation in cancer-predisposition genes was 8.5%. They estimated that in 
the hereditary breast/ovarian cancer (HBOC) from BRCA1 and BRAC2 mutations, 
women with BRCA1 mutations have a 47–66% chance of developing breast cancer 
and a 35–46% chance of developing ovarian cancer by the age of 70 years [2].
Leukaemia is a type of haematological malignancy (liquid cancer) occurring in 
haematopoietic tissue caused by environmental and genetic factors, such as other 
types of cancers, typically presented with fever, bleeding, infection, bone pain and 
anaemia. The presentation can vary, however, depending on the many different fac-
tors of individuals. Among all leukaemia types of the myeloid malignancies, acute 
myeloid leukaemia (AML), myelodysplastic syndrome (MDS) and chronic myeloid 
leukaemia (CML) are the common types.
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In a similar scenario with germline mutations associated with solid cancers, 
about 5–10% of some particular germline mutations will develop to haematologi-
cal malignancies including MDS, MDS/myeloproliferative neoplasms (MPN) and 
AML. Germline predisposition of myeloid malignancies is estimated at about 
5–10% in the genetic manner, either from functional haplo-insufficiency due to loss 
of an allele or gain of oncogenic function, but the loss of an allele is more common 
than gain of oncogenic function in such a type of leukaemia [3].
Studies showed that myeloid neoplasms associated with predisposing of germ-
line mutations are found to be more common than was thought. But it is still under-
investigated, under-diagnosed and under-reported due to the low case numbers and 
nature of disease complexity.
2.  Understanding of the WHO’s germline mutations associated with 
neoplasms from gene mutations and syndromes
To increase the recognition for germline predisposition, the major changes were 
made in the 2016 version of the book WHO Classification of Tumours of Haematopoietic 
and Lymphoid Tissues for the myeloid neoplasms, with the addition of germline predis-
position of the myeloid neoplasms under the following categories [4, 5]:
The first category is myeloid neoplasms with germline predisposition without a 
pre-existing disorder or organ dysfunction with CEBPA and DDX41 mutations.
CCAAT enhancer-binding protein alpha (CEBPA) is involved in the function 
of myeloid differentiation by encoding a granulocyte differentiation factor located 
on chromosome 19q13.1. This germline mutation associated with AML is due to the 
inheritance of a single copy of mutated CEBPA, and studies suggested such muta-
tion has a favourable prognosis than somatic mutation AML [6, 7].
DEAD-Box Helicase (DDX41) is located on chromosome 5q35.3, and studies 
found that in about 1.5% of myeloid neoplasms, half of these patients had germline 
mutations, typically in MDS and AML combined with additional del(5q) presented 
with erythroid dysplasia, leading to erythroid leukaemia with poor prognosis. 
CML, CMML and lymphomas have been also reported [8, 9].
The second category is myeloid neoplasms with germline predisposition and 
pre-existing platelet disorders with RUNX1, ANKRD26 and ETV6 mutations.
Runt-related transcription factor 1 (RUNX1, located on chromosome 21q.12) 
is playing a physiological role in haematopoiesis. RUNX1 mutations cause familial 
platelet disorder and develop to MDS/AML in 11–100% risk, median 44% [10, 11].
Ankyrin repeat domain-containing protein 26 (ANKRD26, located on chromo-
some 10p12.1) mutation is characterised by thrombocytopenia from the abnormal 
megakaryopoiesis and increases risk to MDS and AML in about 30 fold [12, 13].
ETS variant gene 6 (ETV6, located on chromosome 12p13.2) is functional as a hae-
matopoietic regulator in normal physiological condition. ETV6 mutations were found 
to be associated with several types of haematological malignancies including MDS, 
AML, B-cell leukaemia and multiple myeloma (MM) as have been identified [14–17].
The third category is the myeloid neoplasms with germline predisposition 
and other organ dysfunctions with GATA2 mutations and several types of genetic-
based syndromes including myeloid neoplasms associated with telomere biology 
disorders, juvenile myelomonocytic leukaemia associated with neurofibromatosis, 
Noonan syndrome or Noonan syndrome-like disorders and myeloid neoplasms 
associated with Down syndrome.
GATA-binding protein 2 (GATA2, located on chromosome 3q21.3) mutations 
were found to be associated with some syndromes, including MonoMac syndrome, 
dendritic cell, monocyte, B and NK cell deficiency, familial MDS and Emberger 
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syndrome and some types of disorders such as congenital neutropenia and aplastic 
anaemia. The risk of developing MDS/AML from GATA2 germline mutations is 
increased by 70% [18, 19, 20, 21].
3.  Germline mutations associated with haematological malignancies in 
myeloid and lymphoid leukaemias
Most of the findings of germline mutations associated with leukaemia were 
from myeloid neoplasms. Recent studies found that lymphoid malignancies in acute 
lymphoblastic leukaemia (ALL) and chronic lymphocytic leukaemia (CLL) are 
associated with germline mutations. Speedy et al. demonstrated the existence of 
germline mutations associated with familial CLL by using whole-exome sequencing 
of 66 CLL families and identified 4 families where loss-of-function mutations in 
protection of telomeres 1 (POT1) co-segregated with CLL [22]. Qian group studied 
the loss-of-function germline TP53 variants, and their results suggested that such 
mutations lead to predispose children to ALL and with adverse treatment outcomes 
with ALL therapy and increase the risk of second malignant neoplasms [23]. Chang 
et al. have identified germline mutations from congenital ALL by using the exome 
sequencing technology [24].
Studies showed that some more genetic-based cancer-prone syndromes with 
specific germline predisposition syndromes and multiple-cancer hereditary pre-
disposition syndromes are all at an increased risk for haematologic malignancies, 
commonly in AML, including chromosomal instability syndromes (CIS) such as 
Nijmegen breakage syndrome, Ataxia telangiectasia, Ataxia telangiectasia-like 
disorder and Bloom syndrome and including inherited bone marrow failure syn-
dromes (IBMFS) such as dyskeratosis congenita, Shwachman-Diamond syndrome, 
Diamond-Blackfan anaemia, congenital amegakaryocytic thrombocytopenia, 
severe congenital neutropenia and thrombocytopenia-absent radii [25].
The most representative example is the Fanconi anaemia (FA) with germline 
mutations and predisposition to leukaemia. It overlaps in both CIS and IBMFS in its 
phenotypes. Historically, it was first recognised as a cause of juvenile leukaemia in 
1967 [26]. FA is a hereditary disorder with defects in DNA repair and is character-
ised with multiple gene mutations, multiple types of genetic abnormalities, mul-
tiple organ involvements and multiple types of cancer risks [27, 28]. So far, 22 genes 
responsible for FA have been identified, 4 of them are genes found in breast cancer 
and some genes were found to be associated with other types of cancers as well.
Patients with FA have very high susceptibility to both haematologic and non-
haematologic malignancies. The risk of developing AML and MDS is increased 
to 785 fold, and the median age of patients developing to AML is 14 years. AML 
occurs at about 9% and MDS is about 7% of all patients with FA, respectively [29]. 
Cells from FA patient associated with leukaemia showed high sensitive reaction to 
chemotherapies than non-FA patient with leukaemia.
FA was the first successful remarkable milestone in cord blood stem cell trans-
plantation in 1988. The studies on FA offered insights into the pathogenesis of many 
types of human diseases, particularly in non-genetic bone marrow failure, ageing 
and cancer. So the study on FA is named as a paradigm for the understanding of 
cancer and ageing.
In the last couple of years, studies, by using the modern genetic technologies 
particularly by the next-generation sequencing (NGS) approach to study known 
and new germline mutations in familial acute myeloid leukaemia and myelodysplas-
tic syndromes, found more leukaemia predisposition genes associated with germ 
line in variants in cancer-predisposition genes, mainly as ASXL1, BCOR, NRAS, 
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TP53, CEBPA, FLT3, EZH2, IDH1, IDH2, NPM1, DNMT3A, TET2, CBL, KRAS, 
SF3B1, SRSF2, U2AF1, ZRSR2, TERT, TERC and SRP72 [30–32]. Studies from Seiter 
group provided the direct evidence from ASXL1 germline mutation associated 
with leukaemia studied on father and son [33]. Buijs et al. defined CBFA2 single-
nucleotide mutation in a familial leukaemia [34].
Recommendations and guides are available by the applications of the next-
generation sequencing approaches (NGS) [35, 36]. Churpek et al. proposed recom-
mendations on the screening, identification, genetic counselling and managements 
on inherited susceptibility to MDS and acute leukaemia [37].
4. Conclusion
To increase the awareness and recognition for germline mutations associated with 
leukaemia is extremely important and imperative in the clinical practice by perform-
ing the specific tests. The significances are (1) to diagnose such type of patients earlier 
even if before the occurrence of such type of leukaemia, (2) to prevent the occurrence 
of secondary cancers, (3) to care other members of the family, (4) to design a specific 
therapeutical strategy, personalised medicine and long-term follow-up and (5) to 
guide the selection of donors for patient bone marrow stem cell transplantation.
To study germline mutations and syndromes associated with leukaemia has pro-
vided exciting and significant opportunities with such new discoveries. The studies 
on germline mutations associated with leukaemia will not only be useful in its 
clinical diagnosis, classification, stratification and specific treatment strategies, but 
it will also provide an insight to understand human diseases, such as tumorigenesis, 
particularly in somatic mutations associated with leukemogenesis. It is certainly 
that more and more such disorders will be identified in the future.
The huge challenges are to identify germline mutation associated with leukae-
mia due to the lack of awareness and knowledge about these disorders, lack of at 
least easy and practical available testing methods and sufficient familial history of 
individuals and lack of specimen source to represent genome for these individuals. 
The complex and mysterious genetic variation is another challenging issue just as 
the English novelist, George Orwell, described that “all cancer is genetic, but some 
cancers are more genetic than others which it hinted the mechanism and genetic 
variations of cancers”.
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